Pressemeddelelse fra LEO Foundation
The transaction between the LEO Foundation and Nordic Capital, , has been formally closed. Nordic Capital invests EUR 450 million in LEO Pharma and becomes a minority shareholder and partner to the LEO Foundation, who will remain the company’s controlling owner.
“We are excited to close the deal and begin a new chapter in the history of LEO Pharma. With the LEO Foundation as the company’s long-term controlling owner and Nordic Capital as co-owner and partner we provide the company with the best possible platform for future growth and success. We are confident that this new ownership structure will further support the realization of the considerable potential of LEO Pharma – and we look very much forward to partnering with Nordic Capital,” said Jesper Mailind, CEO of the LEO Foundation.
Nordic Capital is one of the most active and experienced investors in healthcare globally. The firm has a strong track record of investing in innovative companies and building industry leaders in close partnership with management teams and co-owners. Since inception in 1989, Nordic Capital has invested more than EUR 7 billion in 29 healthcare investments across Europe and North America. Within pharmaceuticals, Nordic Capital’s current and previous investments include Advanz Pharma, Acino, Nycomed, Fougera, Biovitrum and Meda. Today, Nordic Capital has 14 portfolio companies in the broader healthcare sector with c. 44,000 employees and aggregate revenues in excess of EUR 6 bn.
Kontakt:
LEO Fondet
Signe Krabek, Head of Communication and Public Affairs
Tel: +45 20 49 68 69
Email: signe.krabek@leo-foundation.org
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/the-leo-foundation-announces-closing-of-nordic-capitals-investment-in-leo-pharma?releaseId=13626912
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
